The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients

Clinica Chimica Acta

Volumn 296, Issue 1-2, 2000, Pages 101-109

  Topić, Elizabeta ^a   Štefanović, Mario ^a   Ivanišević, Ana Maria ^a   Petrinović, Rajka ^b   Čurčić, Ivica ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Graphical Institute of Croatia   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

Author keywords

Breast cancer; CYP2D6 polymorphism; Head and neck cancer; PCR SSCP

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ALLELE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CANCER; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALLELES; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FRAMESHIFT MUTATION; GENOTYPE; HEAD AND NECK NEOPLASMS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0034053367     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(00)00221-7     Document Type: Article

References (21)

1. Hong J.Y., Yang C.S. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ Health Perspect. 105:(Suppl 4):1997;759-762.
2. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett. 263:1990;131-133.
3. Taioli E., Trachman J., Chen X., Toniolo P., Garte S.J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 55:1995;3757-3768.
4. Tefre T., Ryberg D., Haugen A., et al. Human CYP1A1 (cytochrome P450 P1450) gene: lack of association between the MspI restriction fragment length polymorphism and the incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1:1991;20-25.
5. Wolf C.R., Smith C.A.D., Gough A.C., et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 13:1993;1035-1038.
6. Hidesheim A., Chen C.-J., Caporaso N.E., et al. Cytochrome P4502E1 genetic polymorphism and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev. 4:1995;607-610.
7. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphism in a Finnish study population. Carcinogenesis. 14:1993;85-88.
8. Kato S., Shields P.G., Caporaso N.E., et al. Analysis of cytochrome P450 2E1 genetic polymorphism in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev. 4:1995;515-518.
9. Yu M.-W., Gladek-Yarborough A., Chiamprasert S., Santella R.M., Liaw Y.-F., Chen C.-J. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphism and susceptibility to hepatocellular carcinoma. Gastroenterology. 109:1995;1266-1273.
10. Stüven T., Griese E.U., Kroemer H.K., Eichelbaum M., Zanger U.M. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics. 6:1996;417-421.
11. Kimura S., Umeno M., Skoda R.C., Meyer U.A., Gonzales F. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 45:1989;889-904.
12. Topic E., Gluhak J. Isolation of restrictible DNA. Eur J Clin Chem Clin Biochem. 29:1991;327-330.
13. Wolf C.R., Moss J.E., Miles J.S., Gough A.C., Spurr N.K. Deletion of debrisoquine hydroxylation phenotypes. Lancet. 335:1990;1452-1453.
14. Vermes I., Bon M., van den Bergh F.A.T.M.J., et al. Pharmacogenetics: a tool for therapeutic drug monitoring pretherapeutic genotyping of CYP2D6. 12th IFCC European Congress of Clinical Chemistry, MEDLAB 97, Switzerland :1997;104. [abstract].
15. Topić E., Štefanović M., Nikolić V., Zoričić I., Ivanišević A.-M., Žuntar I. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism. Clin Chem Lab Med. 36:1998;655-658.
16. Broly F., Marez D., Sabbagh N., et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics. 5:1995;373-384.
17. Gough A.C., Miles J.S., Spurr N.K., et al. Identification of primary gene defect at the cytochrome P450 CYP2D locus. Nature. 347:1990;773-776.
18. Agundez J.A.G., Martinez C., Ladero J.M., et al. Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther. 55:1994;10-14.
19. Smith C.A., Moss J.E., Gough A.C., Spurr N.K., Wolf C.R. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect. 98:1992;107-112.
20. Anthony L.B., Thomas J.B., Hande K.R. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquine and dextromethorphan as probes. Cancer Chemother Pharmacol. 36:1995;125-128.
21. Gonzales M.V., Alvarez V., Pello M.F., Menendez M.J., Suarez C., Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in susceptibility to head and neck cancer. J Clin Pathol. 51:1998;294-298.